167 related articles for article (PubMed ID: 2786139)
1. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342.
McCracken AA; Kruse KB; Brown JL
Mol Cell Biol; 1989 Apr; 9(4):1406-14. PubMed ID: 2786139
[TBL] [Abstract][Full Text] [Related]
2. Construction and expression of alpha 1-proteinase inhibitor mutants and the effects of these mutations on secretion of the variant inhibitors.
McCracken AA; Kruse KB; Valentine J; Roberts C; Yohannes TZ; Brown JL
J Biol Chem; 1991 Apr; 266(12):7578-82. PubMed ID: 2019587
[TBL] [Abstract][Full Text] [Related]
3. Effects of mutations that alter the Glu264-Lys387 salt bridge on the secretion of alpha-1-proteinase inhibitor.
Brodbeck RM; Samandari T; Brown JL
J Biol Chem; 1993 Mar; 268(9):6771-6. PubMed ID: 8454649
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the 290-342 salt bridge is not responsible for the secretory defect of the PiZ alpha 1-antitrypsin variant.
Sifers RN; Hardick CP; Woo SL
J Biol Chem; 1989 Feb; 264(5):2997-3001. PubMed ID: 2563374
[TBL] [Abstract][Full Text] [Related]
5. Selective protein degradation in the yeast exocytic pathway.
McCracken AA; Kruse KB
Mol Biol Cell; 1993 Jul; 4(7):729-36. PubMed ID: 8400458
[TBL] [Abstract][Full Text] [Related]
6. A study of the effects of altering the sites for N-glycosylation in alpha-1-proteinase inhibitor variants M and S.
Samandari T; Brown JL
Protein Sci; 1993 Sep; 2(9):1400-10. PubMed ID: 8401226
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the Lys-290--Glu-342 salt bridge in human alpha 1-antitrypsin does not prevent its synthesis and secretion.
Foreman RC
FEBS Lett; 1987 May; 216(1):79-82. PubMed ID: 2884131
[TBL] [Abstract][Full Text] [Related]
8. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation.
Brantly M; Courtney M; Crystal RG
Science; 1988 Dec; 242(4886):1700-2. PubMed ID: 2904702
[TBL] [Abstract][Full Text] [Related]
9. Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.
Matthiessen HP; Willemse J; Weber A; Turecek PL; Deiteren K; Hendriks D; Ehrlich HJ; Schwarz HP
Transfusion; 2008 Feb; 48(2):314-20. PubMed ID: 18028276
[TBL] [Abstract][Full Text] [Related]
10. Detection of genetic variants of alpha 1-antitrypsin with site-specific monoclonal antibodies.
Zegers ND; Claassen E; Gerritse K; Deen C; Boersma WJ
Clin Chem; 1991 Sep; 37(9):1606-11. PubMed ID: 1893597
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin Mmineral springs allele.
Curiel DT; Vogelmeier C; Hubbard RC; Stier LE; Crystal RG
Mol Cell Biol; 1990 Jan; 10(1):47-56. PubMed ID: 1967187
[TBL] [Abstract][Full Text] [Related]
12. Natural history of alpha-1-protease inhibitor deficiency.
Hutchison DC
Am J Med; 1988 Jun; 84(6A):3-12. PubMed ID: 3289386
[TBL] [Abstract][Full Text] [Related]
13. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
14. The amino acid substitutions of human alpha 1-antitrypsin M3, X and Z.
Jeppsson JO; Laurell CB
FEBS Lett; 1988 Apr; 231(2):327-30. PubMed ID: 3258831
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line.
Wang Z; Hilder TL; van der Drift K; Sloan J; Wee K
Anal Biochem; 2013 Jun; 437(1):20-8. PubMed ID: 23462539
[TBL] [Abstract][Full Text] [Related]
16. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-1-proteinase inhibitor by nitric oxide/isoprene mixtures in air.
Pryor WA; Dooley MM; Church DF
Chem Biol Interact; 1985 Jul; 54(2):171-83. PubMed ID: 3875431
[TBL] [Abstract][Full Text] [Related]
18. Probing the RNA binding surface of the HIV-1 nucleocapsid protein by site-directed mutagenesis.
Ouyang W; Okaine S; McPike MP; Lin Y; Borer PN
Biochemistry; 2013 May; 52(19):3358-68. PubMed ID: 23594178
[TBL] [Abstract][Full Text] [Related]
19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
20. Production and administration to dogs of aerosols of alpha-1-proteinase inhibitor.
Smith RM; Spragg RG
Am J Med; 1988 Jun; 84(6A):48-51. PubMed ID: 3260073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
